Fulgent Genetics Price to Sales Ratio 2015-2025 | FLGT
Historical PS ratio values for Fulgent Genetics (FLGT) over the last 10 years. The current P/S ratio for Fulgent Genetics as of May 30, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Fulgent Genetics P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2025-05-30 | 20.72 | 2.15 | |
| 2025-03-31 | 16.90 | $9.62 | 1.76 |
| 2024-12-31 | 18.47 | $9.41 | 1.96 |
| 2024-09-30 | 21.73 | $9.25 | 2.35 |
| 2024-06-30 | 19.62 | $9.71 | 2.02 |
| 2024-03-31 | 21.70 | $9.63 | 2.25 |
| 2023-12-31 | 28.91 | $9.71 | 2.98 |
| 2023-09-30 | 26.74 | $9.52 | 2.81 |
| 2023-06-30 | 37.03 | $10.13 | 3.66 |
| 2023-03-31 | 31.22 | $11.87 | 2.63 |
| 2022-12-31 | 29.78 | $19.88 | 1.50 |
| 2022-09-30 | 38.12 | $25.82 | 1.48 |
| 2022-06-30 | 54.53 | $29.71 | 1.84 |
| 2022-03-31 | 62.41 | $30.67 | 2.03 |
| 2021-12-31 | 100.59 | $32.10 | 3.13 |
| 2021-09-30 | 89.95 | $36.24 | 2.48 |
| 2021-06-30 | 92.23 | $33.25 | 2.77 |
| 2021-03-31 | 96.62 | $29.02 | 3.33 |
| 2020-12-31 | 52.10 | $17.70 | 2.94 |
| 2020-09-30 | 40.04 | $5.88 | 6.81 |
| 2020-06-30 | 16.00 | $2.09 | 7.64 |
| 2020-03-31 | 10.76 | $1.78 | 6.04 |
| 2019-12-31 | 12.90 | $1.72 | 7.51 |
| 2019-09-30 | 10.39 | $1.58 | 6.56 |
| 2019-06-30 | 6.68 | $1.37 | 4.89 |
| 2019-03-31 | 5.95 | $1.22 | 4.86 |
| 2018-12-31 | 3.17 | $1.19 | 2.66 |
| 2018-09-30 | 3.93 | $1.12 | 3.52 |
| 2018-06-30 | 4.14 | $1.06 | 3.92 |
| 2018-03-31 | 4.00 | $1.02 | 3.93 |
| 2017-12-31 | 4.38 | $1.05 | 4.18 |
| 2017-09-30 | 4.79 | $1.23 | 3.88 |
| 2017-06-30 | 6.39 | $1.37 | 4.66 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.631B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.506B | 58.15 |
| Hims & Hers Health (HIMS) | United States | $12.660B | 131.54 |
| Tempus AI (TEM) | United States | $9.553B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.486B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $4.076B | 63.69 |
| Hinge Health (HNGE) | United States | $3.030B | 0.00 |
| Privia Health (PRVA) | United States | $2.775B | 189.67 |
| Enovis (ENOV) | United States | $1.788B | 9.97 |
| Clover Health Investments (CLOV) | United States | $1.598B | 0.00 |
| Schrodinger (SDGR) | United States | $1.586B | 0.00 |
| Phreesia (PHR) | United States | $1.457B | 0.00 |
| Omnicell (OMCL) | United States | $1.423B | 25.10 |
| Azenta (AZTA) | United States | $1.223B | 56.85 |
| 10x Genomics (TXG) | United States | $1.173B | 0.00 |
| Claritev (CTEV) | United States | $0.632B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.593B | 0.00 |
| Talkspace (TALK) | United States | $0.534B | 159.50 |
| Veradigm (MDRX) | United States | $0.466B | 0.00 |
| Standard BioTools (LAB) | United States | $0.384B | 0.00 |
| TruBridge (TBRG) | United States | $0.360B | 797.67 |
| Outset Medical (OM) | United States | $0.311B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.264B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.261B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.200B | 0.00 |
| Pulmonx (LUNG) | United States | $0.137B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.136B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.125B | 0.00 |
| American Well (AMWL) | United States | $0.105B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.100B | 0.00 |
| CareCloud (CCLD) | United States | $0.085B | 3.26 |
| 111 (YI) | China | $0.071B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.053B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.037B | 0.00 |
| Zhongchao (ZCMD) | China | $0.029B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.026B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.016B | 0.00 |
| Precipio (PRPO) | United States | $0.014B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |